Critical Review: Altimmune (NASDAQ:ALT) vs. Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Risk & Volatility

Caribou Biosciences has a beta of 2.5, indicating that its share price is 150% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.16, indicating that its share price is 84% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Caribou Biosciences and Altimmune, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1	4	1	1	2.29
Altimmune	1	1	8	0	2.70

Caribou Biosciences currently has a consensus price target of $4.50, suggesting a potential upside of 1,143.44%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 771.33%. Given Caribou Biosciences’ higher probable upside, equities research analysts clearly believe Caribou Biosciences is more favorable than Altimmune.

Insider and Institutional Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 78.0% of Altimmune shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Caribou Biosciences and Altimmune”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16 million	3.50	-$148.12 million	($1.03)	-0.35
Altimmune	$40,000.00	7,999.64	-$88.09 million	($0.78)	-2.11

Altimmune has lower revenue, but higher earnings than Caribou Biosciences. Altimmune is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Caribou Biosciences and Altimmune’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,085.00%	-102.74%	-69.45%
Altimmune	N/A	-31.84%	-27.40%

Summary

Altimmune beats Caribou Biosciences on 9 of the 15 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc. is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. Its work focuses on allogeneic, or donor-derived, CAR-T cell treatments designed to be manufactured for use by multiple patients. The company uses its chRDNA genome-editing platform, which combines CRISPR RNA with DNA components, to make targeted changes to cells. Its clinical programs include CAR-T candidates directed at targets such as CD19 and BCMA, which are being developed for certain blood cancers.

About Altimmune

Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.